AGY

Allergy Therapeutics successful primary outcome of VLP Peanut 001

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has announced positive primary results from an ex-vivo biomarker study evaluating the Group’s novel virus-like particle (VLP)

What you don’t know about food allergies

Pollen-food reactions, adult onset symptoms and cross reactivity are just some of the surprising ways our bodies respond to food. My grandson Tomas first noticed a distressing reaction to hazelnuts

STRIX GROUP PLC ORD 1P
Strix Group plc CEO Mark Bartlett discusses the company's focus on safety controls, global reach, innovation, and growth opportunities for investors.
Firering Strategic MineralS PLC
Learn about Firering Strategic Minerals plc's operations and future plans from an exclusive interview with their Independent Non-Executive Director, Vassilios Carellas.
Pulsar Helium Inc
Discover insights into the helium sector as Stephane Foucard delves into the projects of junior companies, assessing key criteria for commercial viability.
Golden Matrix Group Inc
Golden Matrix Group Inc. CEO Brian Goodman discusses revenue growth, acquisitions, and global markets in an exclusive interview with DirectorsTalk.
XP Factory plc
XP Factory plc's CEO discusses financial highlights, growth targets, and a £10 million credit facility with Barclays in an exclusive interview with DirectorsTalk.